KR20000061432A - Sp-peg-헤모글로빈 결합체 - Google Patents
Sp-peg-헤모글로빈 결합체 Download PDFInfo
- Publication number
- KR20000061432A KR20000061432A KR1019990010469A KR19990010469A KR20000061432A KR 20000061432 A KR20000061432 A KR 20000061432A KR 1019990010469 A KR1019990010469 A KR 1019990010469A KR 19990010469 A KR19990010469 A KR 19990010469A KR 20000061432 A KR20000061432 A KR 20000061432A
- Authority
- KR
- South Korea
- Prior art keywords
- peg
- hemoglobin
- minutes
- animals
- administration
- Prior art date
Links
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 40
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 23
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 23
- AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims description 34
- 239000002202 Polyethylene glycol Substances 0.000 claims description 22
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 3
- QXZGLTYKKZKGLN-UHFFFAOYSA-N 4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)ON1C(=O)CCC1=O QXZGLTYKKZKGLN-UHFFFAOYSA-N 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 abstract description 18
- 238000000034 method Methods 0.000 abstract description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 10
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 abstract description 8
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 abstract description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 5
- 239000011780 sodium chloride Substances 0.000 abstract description 5
- 210000003743 erythrocyte Anatomy 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 235000019260 propionic acid Nutrition 0.000 abstract description 4
- 229910019142 PO4 Inorganic materials 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 3
- 239000010452 phosphate Substances 0.000 abstract description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 abstract description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 abstract description 2
- 238000011026 diafiltration Methods 0.000 abstract description 2
- 229920001427 mPEG Polymers 0.000 abstract description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 abstract description 2
- 238000000108 ultra-filtration Methods 0.000 abstract description 2
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 238000009835 boiling Methods 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 52
- 238000012360 testing method Methods 0.000 description 42
- 230000000694 effects Effects 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 238000001990 intravenous administration Methods 0.000 description 14
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 239000000546 pharmaceutical excipient Substances 0.000 description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 12
- 239000013642 negative control Substances 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- 108010031004 PEG-hemoglobin Proteins 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000002861 ventricular Effects 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 208000007101 Muscle Cramp Diseases 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 208000005392 Spasm Diseases 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- -1 ethyl propionate compound Chemical class 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010060891 General symptom Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001773 anti-convulsant effect Effects 0.000 description 3
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 3
- 229910001626 barium chloride Inorganic materials 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229960005152 pentetrazol Drugs 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108010003320 Carboxyhemoglobin Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000008002 Krebs-Henseleit bicarbonate buffer Substances 0.000 description 1
- 108010061951 Methemoglobin Proteins 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 229940084927 diazepam 10 mg Drugs 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229960002456 hexobarbital Drugs 0.000 description 1
- UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000011046 pyrogen test Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 238000010825 rotarod performance test Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 229960003279 thiopental Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 238000007817 turbidimetric assay Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
구성성분 | 양 |
SP-PEG-헤모글로빈 농도(g/dl) | 5 - 6 |
헤모글로빈 농도 | 2.5 - 3 |
옥시헤모글로빈(%) | 80.0 - 90.0 |
메테모글로빈(Methemoglobin,%) | 0 - 15 |
카르복시헤모글로빈(%) | 4 - 6 |
p50(mmHg) | 9.6 - 11.1 |
힐 계수(Hill coefficient) | 1.5 |
점도(cp) | 3.9 - 4.1 |
팽압(mmHg) | 22 - 23 |
삼투압(Osmolarity, mOsm) | 310 - 320 |
인지질과 기타 불순물 | 포착되지 않음 |
엔도톡신(EU/ml) | 0.05 - 0.5 |
Free Iron(mg/dl) | 1.1 - 2.21 |
스테릴리티(Sterility) | 패스 |
저장 안정성(Storage Stability) | 실온에서 24시간-20℃에서 2년 |
시험군 | 암수 | 동물수 | 투여속도(ml/kg/hr) | 투여량 | |
(ml/kg) | (mg/kg) | ||||
음성대조군 | 수컷 | 5 | 25 | 50 | 0 |
암컷 | 5 | 25 | 50 | 0 | |
T1 | 수컷 | 5 | 25 | 12.5 | 875 |
암컷 | 5 | 25 | 12.5 | 875 | |
T2 | 수컷 | 5 | 25 | 25 | 1750 |
암컷 | 5 | 25 | 25 | 1750 | |
T3 | 수컷 | 5 | 25 | 50 | 3500 |
암컷 | 5 | 25 | 50 | 3500 |
시험군 | 암수 | 동물수 | 투여속도(ml/kg/hr) | 투여량 | |
(ml/kg) | (mg/kg) | ||||
음성대조군 | 수컷 | 2 | 25 | 25 | 0 |
암컷 | 2 | 25 | 25 | 0 | |
T1 | 수컷 | 2 | 25 | 6.25 | 875 |
암컷 | 2 | 25 | 6.25 | 875 | |
T2 | 수컷 | 2 | 25 | 12.5 | 1750 |
암컷 | 2 | 25 | 12.5 | 1750 | |
T3 | 수컷 | 2 | 25 | 25 | 3500 |
암컷 | 2 | 25 | 25 | 3500 |
약명 | 투약량 | 루트 | 동물수 | 이상증세 발현 동물수 | |||||
0분 | 15분 | 30분 | 60분 | 120분 | 240분 | ||||
부형약(Vehicle) | 20ml/kg | i.v. | 8 | 0 | 0 | 0 | 0 | 0 | 0 |
SP-PEG-헤모글로빈 | 5ml/kg | i.v. | 8 | 0 | 0 | 0 | 0 | 0 | 0 |
10ml/kg | i.v. | 8 | 0 | 0 | 0 | 0 | 0 | 0 | |
20ml/kg | i.v. | 8 | 0 | 0 | 0 | 0 | 0 | 0 | |
디아제팜(Diazepam) | 6mg/kg | i.p. | 8 | 0 | 7 | 7 | 5 | 2 | 0 |
약명 | 투약량 | 루트 | 동물수 | 수면시간 | 편차(%) |
부형약 | 20ml/kg | i.v. | 8 | 49.8±5.0 | 100 |
SP-PEG-헤모글로빈 | 5ml/kg | i.v. | 8 | 57.6±8.8 | 116 |
10ml/kg | i.v. | 8 | 56.1±10.5 | 113 | |
20ml/kg | i.v. | 8 | 60.3±12.9 | 121 | |
클로로프로마진(Chloropromazine) | 6mg/kg | i.p. | 8 | 189.4±43.1 | 380 |
약명 | 투약량(ml/kg) | 루트 | 동물수 | 이상증세 발현 동물수 | |||||
0분 | 15분 | 30분 | 60분 | 120분 | 240분 | ||||
부형약(Vehicle) | 20 | i.v. | 8 | 36.6±0.50 | 37.5±0.3 | 37.3±0.2 | 37.3±0.3 | 37.0±0.3 | 36.6±0.4 |
SP-PEG-헤모글로빈 | 5 | i.v. | 8 | 36.8±0.4 | 36.9±0.5 | 37.1±0.4 | 37.2±0.5 | 37.4±0.3 | 36.9±0.3 |
10 | i.v. | 8 | 37.0±0.5 | 36.9±0.5 | 37.1±0.4 | 37.3±0.4 | 37.6±0.5 | 37.0±0.4 | |
20 | i.v. | 8 | 36.8±0.3 | 37.3±0.4 | 37.3±0.4 | 37.3±0.4 | 37.2±0.2 | 37.1±0.4 |
약명 | 투약량 | 루트 | 동물수 | 뤼드의 수(wriths, No) |
부형약 | 20ml/kg | i.v. | 8 | 13.5±3.4 |
SP-PEG-헤모글로빈 | 5ml/kg | i.v. | 8 | 14.3±3.5 |
10ml/kg | i.v. | 8 | 15.0±3.4 | |
20ml/kg | i.v. | 8 | 14.9±3.8 | |
케토프로펜(ketoprofen) | 10mg/kg | i.p. | 8 | 6.1±3.6 |
약명 | 투약량 | 루트 | 동물수 | 리킹타임(sec) |
부형약 | 20ml/kg | i.v. | 8 | 4.2±0.6 |
SP-PEG-헤모글로빈 | 5ml/kg | i.v. | 8 | 4.2±1.0 |
10ml/kg | i.v. | 8 | 4.5±1.4 | |
20ml/kg | i.v. | 8 | 4.4±0.8 | |
코데인(codeine) | 100mg/kg | i.p. | 8 | 13.2±6.1 |
약명 | 투약량 | 루트 | 경련(No) | TE 타임(sec) | 프로텍션(%) |
부형약 | 20ml/kg | i.v. | 8/8 | 57.6±8.8 | 0 |
SP-PEG-헤모글로빈 | 5ml/kg | i.v. | 8/8 | 59.9±21.1 | 0 |
10ml/kg | i.v. | 8/8 | 61.5±20.8 | 0 | |
20ml/kg | i.v. | 8/8 | 67.6±42.1 | 0 | |
코데인(Codeine) | 100mg/kg | i.p. | 0/8 | - | 100 |
약명 | 투약량 | 루트 | 경련(No) | TE 타임(sec) | 프로텍션(%) |
부형약 | 20ml/kg | i.v. | 8/8 | 164.5±39.5 | 0 |
SP-PEG-헤모글로빈 | 5ml/kg | i.v. | 8/8 | 148.0±30.6 | 0 |
10ml/kg | i.v. | 8/8 | 169.9±27.1 | 0 | |
20ml/kg | i.v. | 8/8 | 170.4±27.1 | 0 | |
디아제팜 | 10mg/kg | i.p. | 4/8 | 286.8±32.8 | 50 |
약명 | 투약량 | 루트 | 경련(No) | 프로텍션(%) |
부형약 | 20ml/kg | i.v. | 8/8 | 0 |
SP-PEG-헤모글로빈 | 5ml/kg | i.v. | 8/8 | 0 |
10ml/kg | i.v. | 8/8 | 0 | |
20ml/kg | i.v. | 8/8 | 0 | |
디아제팜 | 20mg/kg | i.p. | 8/8 | 0 |
시간(분) | 부형약 | 5ml/kg | 10ml/kg | 20ml/kg | ||||
평균(%) | S.E.M. | 평균(%) | S.E.M. | 평균(%) | S.E.M. | 평균(%) | S.E.M. | |
0 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
10 | 2.13 | 2.89 | -4.48 | 3.76 | 7.76 | 4.76 | 1.26 | 2.06 |
20 | 1.96 | 3.61 | 0.88 | 2.77 | 9.05 | 6.57 | -0.05 | 3.95 |
30 | 3.45 | 5.24 | 1.09 | 3.34 | 14.04 | 4.62 | 4.44 | 4.71 |
60 | -5.02 | 2.29 | -1.96 | 2.68 | 12.49 | 4.76 | 6.41 | 2.01 |
90 | -4.44 | 3.76 | -3.69 | 1.54 | 10.05 | 5.50 | 4.95 | 4.73 |
120 | -4.34 | 3.72 | -5.51 | 2.46 | 6.72 | 5.37 | 8.81 | 2.48 |
240 | -5.93 | 5.54 | -8.55 | 2.97 | 7.44 | 4.76 | -2.66 | 3.15 |
360 | -2.67 | 6.95 | -7.93 | 1.84 | 7.95 | 5.08 | -3.72 | 3.38 |
베이스라인(mmHg) | 88.0 | 4.80 | 103.1 | 3.9 | 90.3 | 6.9 | 101.3 | 3.5 |
시간(분) | 부형약 | 5ml/kg | 10ml/kg | 20ml/kg | ||||
평균(%) | S.E.M. | 평균(%) | S.E.M. | 평균(%) | S.E.M. | 평균(%) | S.E.M. | |
0 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
10 | 0.65 | 3.85 | 0.16 | 3.80 | -0.82 | 3.11 | 3.39 | 1.50 |
20 | 1.30 | 3.46 | -5.64 | 3.99 | 0.48 | 2.75 | -0.46 | 1.73 |
30 | 0.85 | 5.89 | 1.80 | 7.02 | 0.01 | 1.97 | -0.02 | 2.62 |
60 | 2.97 | 3.55 | -3.34 | 2.43 | 3.45 | 1.66 | 0.74 | 1.48 |
90 | 4.10 | 3.78 | -6.68 | 4.61 | 5.25 | 2.74 | 1.99 | 2.28 |
120 | 2.66 | 3.24 | 1.86 | 2.84 | 4.46 | 2.43 | 2.96 | 1.85 |
240 | 2.97 | 5.11 | 0.31 | 3.11 | 2.64 | 2.67 | 6.11 | 1.67 |
360 | 3.53 | 2.68 | -1.30 | 3.99 | -2.34 | 4.08 | 1.08 | 2.52 |
베이스라인(mmHg) | 294.9 | 6.53 | 294.9 | 15.73 | 275.8 | 14.29 | 269.8 | 13.84 |
약명 | 투약량(ml/kg) | 호흡률(rate/분) | ||||
0분 | 15분 | 30분 | 60분 | 120분 | ||
부형약 | 20 | 105.2±5.9 | 117.0±16.9 | 102.3±16.6 | 103.9±8.9 | 98.8±9.4 |
SP-PEG-헤모글로빈 | 5 | 102.7±4.2 | 99.6±5.5 | 98.9±3.3 | 101.8±4.5 | 96.3±1.6 |
10 | 106.7±7.3 | 114.4±11.1 | 107.0±4.8 | 111.8±8.0 | 102.5±4.6 | |
20 | 109.3±9.1 | 112.2±11.4 | 99.2±6.2 | 99.1±4.9 | 96.8±6.6 |
약명 | 투약량(ml/kg) | 호흡체적(ml) | ||||
0분 | 15분 | 30분 | 60분 | 120분 | ||
부형약 | 20 | 2.9±0.2 | 2.5±0.2 | 2.9±0.4 | 2.8±0.4 | 2.9±0.2 |
SP-PEG-헤모글로빈 | 5 | 2.4±0.7 | 2.1±0.3 | 2.6±0.6 | 2.2±0.4 | 2.2±0.3 |
10 | 2.5±0.5 | 2.1±0.5 | 2.0±0.2 | 2.5±0.3 | 2.2±0.2 | |
20 | 2.8±0.7 | 2.1±0.5 | 2.4±0.2 | 2.3±0.6 | 2.4±0.4 |
약명 | log[M] | 수축 응답(Contractile Responses, %) | |||
전치치없음 | 아세티콜린 | 히스타민 | 염화바륨 | ||
평균(S.E.M.) | 평균(S.E.M.) | 평균(S.E.M.) | 평균(S.E.M.) | ||
부형약 | 0 | 0.00(0.0) | 146.5(6.1) | 148.3(7.8) | 124.8(6.0) |
SP-PEG-헤모글로빈 | 5 | 0.00(0.0) | 152.3(3.8) | 138.6(10.1) | 133.9(5.8) |
10 | 0.00(0.0) | 156.4(3.8) | 129.1(7.7) | 134.2(2.9) | |
20 | 0.00(0.0) | 161.5(5.1) | 132.9(7.7) | 131.5(7.3) | |
N | 8 | 8 | 8 | 8 |
약명 | 투약량 | 루트 | 동물수 | 체적(ml) | pH | 총산도(μEq) |
부형약 | 20ml/kg | i.v. | 5 | 11.9±1.9 | 1.44±0.24 | 108.6±111.7 |
SP-PEG-헤모글로빈 | 5ml/kg | i.v. | 5 | 10.7±0.7 | 1.10±0.07 | 893.1±87.8 |
10ml/kg | i.v. | 5 | 10.5±1.1 | 1.24±0.17 | 929.2±145.0 | |
20ml/kg | i.v. | 5 | 12.5±1.1 | 1.12±0.04 | 1209.2±136.6 | |
아트로핀 | 1mg/kg | i.p. | 5 | 5.8±1.2 | 1.20±0.00 | 587.9±149.2 |
약명 | 투약량 | 루트 | pH | 소변량(ml) | Na+(mmol/L) | Cl-(mmol/L) | K+(mmol/L) |
부형약 | 20ml/kg | i.v. | 7.0±0.0 | 2.8±0.3 | 80.7±3.2 | 105.38.1 | 44.3±9.6 |
SP-PEG-헤모글로빈 | 5ml/kg | i.v. | 7.0±0.0 | 2.3±0.5 | 54.7±10.1 | 71.03.6 | 37.0±13.1 |
10ml/kg | i.v. | 7.0±0.0 | 2.7±0.3 | 64.7±28.1 | 84.032.2 | 28.0±2.6 | |
20ml/kg | i.v. | 7.0±0.0 | 3.9±1.2 | 55.3±31.1 | 88.312.7 | 30.3±10.2 | |
퓨로세미드(Furosemide) | 1mg/kg | i.p. | 7.0±0.0 | 6.0±1.8 | 133.0±4.0 | 161.722.2 | 30.3±6.5 |
Claims (4)
- 다음 화학식 1의 SP-PEG-헤모글로빈 결합체.[화학식 1]
- 제 1 항에 있어서, 상기 물질은 폴리에틸렌 글리콜 숙시니미딜 프로피오네이트와 헤모글로빈을 함께 반응시켜 얻은 것임을 특징으로 하는 SP-PEG-헤모글로빈 결합체.
- 제 2 항에 있어서, 상기 폴리에틸렌 글리콜 숙시니미딜 프로피오네이트는 폴리에틸렌 글리콜을 에틸 아크릴레이트와 N-하이드록시 숙시니미드와 함께 반응시켜 얻은 것임을 특징으로 하는 SP-PEG-헤모글로빈 결합체.
- 제 2 항에 있어서, 상기 폴리에틸렌 글리콜 숙시니미딜 숙시네이트는 분자량이 100-200,000Dalton인 것을 특징으로 하는 SP-PEG-헤모글로빈 결합체.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990010469A KR100316154B1 (ko) | 1999-03-26 | 1999-03-26 | 폴리에틸렌글리콜-헤모글로빈 결합체 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990010469A KR100316154B1 (ko) | 1999-03-26 | 1999-03-26 | 폴리에틸렌글리콜-헤모글로빈 결합체 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20000061432A true KR20000061432A (ko) | 2000-10-16 |
KR100316154B1 KR100316154B1 (ko) | 2001-12-12 |
Family
ID=19577843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019990010469A KR100316154B1 (ko) | 1999-03-26 | 1999-03-26 | 폴리에틸렌글리콜-헤모글로빈 결합체 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100316154B1 (ko) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005042563A3 (en) * | 2003-10-22 | 2005-08-25 | Akzo Nobel Nv | Process for incrasing protein pegylation reaction yields by diafiltration ultrafiltration |
US10821158B2 (en) | 2013-03-15 | 2020-11-03 | William Schindler | Polyalkylene oxide valerate hemoglobin conjugates |
WO2021261712A1 (en) * | 2020-06-26 | 2021-12-30 | Sunbio, Inc. | Hemoglobin derivative co-conjugated with fatty acid-linked peg and alkoxy peg as a blood substitute |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100550206B1 (ko) * | 2002-03-18 | 2006-02-08 | 한국과학기술원 | 상피세포성장인자와 폴리에틸렌글리콜의 접합체 및 이의제조방법 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6023084B2 (ja) * | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
JPS6153223A (ja) * | 1984-08-22 | 1986-03-17 | Ajinomoto Co Inc | ヘモグロビン−ポリアルキレングリコ−ル結合体の製造方法 |
US5234903A (en) * | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
US5414135A (en) * | 1991-12-30 | 1995-05-09 | Sterling Winthrop Inc. | Vinyl sulfone coupling of polyoxyalkylenes to proteins |
-
1999
- 1999-03-26 KR KR1019990010469A patent/KR100316154B1/ko not_active IP Right Cessation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005042563A3 (en) * | 2003-10-22 | 2005-08-25 | Akzo Nobel Nv | Process for incrasing protein pegylation reaction yields by diafiltration ultrafiltration |
US10821158B2 (en) | 2013-03-15 | 2020-11-03 | William Schindler | Polyalkylene oxide valerate hemoglobin conjugates |
WO2021261712A1 (en) * | 2020-06-26 | 2021-12-30 | Sunbio, Inc. | Hemoglobin derivative co-conjugated with fatty acid-linked peg and alkoxy peg as a blood substitute |
US20210401949A1 (en) * | 2020-06-26 | 2021-12-30 | Sunbio, Inc. | Hemoglobin Derivative Co-conjugated with Fatty Acid-linked PEG and Alkoxy PEG as a Blood Substitute |
Also Published As
Publication number | Publication date |
---|---|
KR100316154B1 (ko) | 2001-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Raventos | The action of Fluothane—a new volatile anaesthetic | |
US7888332B2 (en) | Hydrazide-containing CFTR inhibitor compounds and uses thereof | |
Frankel et al. | Glutamine enhancement of structure and function in transplanted small intestine in the rat | |
JPS6263514A (ja) | 組織に酸素を与えるための装置 | |
US5082831A (en) | Total body washout solution and method of use | |
US20100204332A1 (en) | Method for treating a disease or condition responsive to opening of c1c-2 channel | |
WO1998019996A1 (en) | Nitric oxide donor compounds and pharmaceutical compositions for pulmonary hypertension and other indications | |
JP2003535132A (ja) | うっ血性心不全治療用プロスタグランジン化合物 | |
CA1246449A (en) | Drug kit or drug composition for ischaemic damage | |
Letts et al. | Effects of intra-coronary administration of leukotriene D4 in the anaesthetized dog | |
KR20000061432A (ko) | Sp-peg-헤모글로빈 결합체 | |
CN105283181A (zh) | 多官能氮氧衍生物的前药及其用途 | |
US7442383B2 (en) | Use of xenon for the control of neurological deficits associated with cardiopulmonary bypass | |
WO2001015525A1 (fr) | Conservateurs pour organes | |
Oldhafer et al. | Liver transplantation in pigs: a model for studying reperfusion injury | |
Gristwood et al. | Pharmacological studies with SK&F 94120, a novel positive inotropic agent with vasodilator activity | |
WO2002011741A1 (en) | Cardioplegic solution | |
Herrtage et al. | Surgical correction of the tetralogy of Fallot in a dog | |
CN104840479A (zh) | Nadph在制备治疗心脏疾病药物中的应用 | |
RU2815501C1 (ru) | Раствор для предтрансплантационной подготовки донорских легких | |
KANEKO et al. | A simple, working heart and lung transplant model for assessing preservation methods in the rabbit | |
US20230321196A1 (en) | Medicine for Preventing or Treating Symptom or Disorder in Subject Affected by Viral Infection | |
KR20110094321A (ko) | 수식형 수퍼옥사이드 디스뮤타아제 함유 흡입제 | |
Lohse et al. | Dissolution, solubility and protein composition OP human pancreatic stones | |
Cooper | Haemodynamic studies during short-term preservation of the autoperfusing heart-lung preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121210 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20131118 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20141117 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20151117 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20161115 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20171116 Year of fee payment: 17 |
|
FPAY | Annual fee payment |
Payment date: 20181112 Year of fee payment: 18 |
|
EXPY | Expiration of term |